ClinicalTrials.Veeva

Menu

Prognostic Value of PtcO2 in Patients With COVID-19

S

Southeast University, China

Status

Enrolling

Conditions

COVID-19 Acute Respiratory Distress Syndrome

Treatments

Other: outcome
Other: Subtype of COVID-19

Study type

Observational

Funder types

Other

Identifiers

NCT05682612
2023ZDSYLL001-P01

Details and patient eligibility

About

Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission, such patients often have abnormal oxygen tolerance. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.

Full description

Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission. Attention should be paid to patients over 65 years of age who have severe underlying diseases (cancer, respiratory diseases, cardiovascular and cerebrovascular diseases, chronic renal failure, autoimmune deficiency diseases, etc.) and have not completed the whole course of vaccine, and such patients often have abnormal oxygen tolerance, that is, a significant decrease in skin finger pulse oxygen saturation (SpO2) can occur after daily activities. Basal SpO2 at admission is often associated with prognosis, but it is difficult to differentiate prognosis from responsiveness to treatment by changes in SpO2 after oxygen therapy is administered clinically. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age: 18-80 years, male or female; Patients with COVID-9 pneumonia (typical imaging features of COVID-19 pneumonia) (oxygen saturation ≤ 93% during air or arterial partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg at rest);

Exclusion criteria

  • Pregnant or lactating women; Patients who refuse to undergo transcutaneous tissue oxygen pressure monitoring; Clinicians believe that patients are not appropriate; Patients undergoing ECMO.

Trial design

40 participants in 2 patient groups

Survivors
Description:
Survivors of COVID-19 induced respiratory failure
Treatment:
Other: Subtype of COVID-19
Other: outcome
Nonsurvivors
Description:
Nonsurvivors of COVID-19 induced respiratory failure
Treatment:
Other: Subtype of COVID-19
Other: outcome

Trial contacts and locations

1

Loading...

Central trial contact

Jingyuan Xu, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems